United Therapeutics Corporation NASDAQ:UTHR

Founder-led company

United Therapeutics stock price today

$313.22
-46.73
-12.98%
Financial Health
0
1
2
3
4
5
6
7
8
9

United Therapeutics stock price monthly change

+12.00%
month

United Therapeutics stock price quarterly change

+12.00%
quarter

United Therapeutics stock price yearly change

+67.52%
year

United Therapeutics key metrics

Market Cap
16.07B
Enterprise value
10.13B
P/E
15.47
EV/Sales
5.23
EV/EBITDA
9.79
Price/Sales
5.31
Price/Book
2.14
PEG ratio
0.30
EPS
22.38
Revenue
2.49B
EBITDA
1.46B
Income
1.05B
Revenue Q/Q
33.69%
Revenue Y/Y
26.09%
Profit margin
37.56%
Oper. margin
50.6%
Gross margin
92.17%
EBIT margin
50.6%
EBITDA margin
58.78%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

United Therapeutics stock price history

United Therapeutics stock forecast

United Therapeutics financial statements

Average Price Target
Last Year

$458

Potential upside: 46.22%

Based on estimate of 4 analysts
  • Analysts Price target

  • Financials & Ratios estimates

United Therapeutics Corporation (NASDAQ:UTHR): Profit margin
Jun 2023 596.5M 259.2M 43.45%
Sep 2023 609.4M 267.6M 43.91%
Dec 2023 614.7M 217.1M 35.32%
Mar 2024 677.7M 306.6M 45.24%
United Therapeutics Corporation (NASDAQ:UTHR): Debt to assets
Jun 2023 6681300000 1.27B 19.01%
Sep 2023 7023600000 1.31B 18.67%
Dec 2023 7167000000 1.18B 16.5%
Mar 2024 6495200000 1.15B 17.81%
United Therapeutics Corporation (NASDAQ:UTHR): Cash Flow
Jun 2023 106.3M -227.2M 24.7M
Sep 2023 346.2M -313.4M 7.6M
Dec 2023 150.7M 42.1M -92.8M
Mar 2024 376.5M 735.3M -1.06B

United Therapeutics alternative data

United Therapeutics Corporation (NASDAQ:UTHR): Employee count
Aug 2023 985
Sep 2023 985
Oct 2023 985
Nov 2023 985
Dec 2023 985
Jan 2024 985
Feb 2024 985
Mar 2024 1,168
Apr 2024 1,168
May 2024 1,168
Jun 2024 1,168
Jul 2024 1,168

United Therapeutics other data

84.33% -5.56%
of UTHR is owned by hedge funds
40.56M -2.31M
shares is hold by hedge funds

United Therapeutics Corporation (NASDAQ:UTHR): Insider trades (number of shares)
Period Buy Sel
Apr 2024 0 14400
May 2024 0 115070
Jun 2024 0 21600
Nov 2024 0 60555
Dec 2024 0 27700
Transaction Date Insider Security Shares Price per share Total value Source
Option
BENKOWITZ MICHAEL officer: PRESIDEN.. Stock Options 2,500 $111 $277,500
Sale
BENKOWITZ MICHAEL officer: PRESIDEN.. Common Stock 215 $364.92 $78,457
Sale
BENKOWITZ MICHAEL officer: PRESIDEN.. Common Stock 1,300 $367.73 $478,052
Sale
BENKOWITZ MICHAEL officer: PRESIDEN.. Common Stock 2,700 $368.29 $994,370
Sale
BENKOWITZ MICHAEL officer: PRESIDEN.. Common Stock 607 $368.48 $223,664
Sale
BENKOWITZ MICHAEL officer: PRESIDEN.. Common Stock 100 $370.75 $37,075
Sale
BENKOWITZ MICHAEL officer: PRESIDEN.. Common Stock 178 $371.57 $66,139
Option
BENKOWITZ MICHAEL officer: PRESIDEN.. Stock Options 4,500 $102.11 $459,495
Sale
BENKOWITZ MICHAEL officer: PRESIDEN.. Common Stock 926 $366.27 $339,167
Option
BENKOWITZ MICHAEL officer: PRESIDEN.. Common Stock 4,500 $102.11 $459,495
Patent
Application
Filling date: 2 Mar 2022 Issue date: 8 Sep 2022
Application
Filling date: 29 Mar 2022 Issue date: 14 Jul 2022
Application
Filling date: 17 Jan 2022 Issue date: 7 Jul 2022
Grant
Filling date: 15 Jul 2020 Issue date: 5 Jul 2022
Grant
Filling date: 27 Sep 2021 Issue date: 14 Jun 2022
Application
Filling date: 31 Jan 2022 Issue date: 19 May 2022
Grant
Filling date: 6 Oct 2021 Issue date: 5 Apr 2022
Application
Filling date: 8 Sep 2021 Issue date: 3 Mar 2022
Grant
Filling date: 30 Nov 2020 Issue date: 1 Feb 2022
Application
Filling date: 6 Oct 2021 Issue date: 27 Jan 2022
Friday, 29 November 2024
zacks.com
Friday, 15 November 2024
seekingalpha.com
seekingalpha.com
Thursday, 14 November 2024
seekingalpha.com
Tuesday, 5 November 2024
businesswire.com
zacks.com
Monday, 4 November 2024
zacks.com
Friday, 1 November 2024
zacks.com
Wednesday, 30 October 2024
seekingalpha.com
zacks.com
zacks.com
businesswire.com
Tuesday, 29 October 2024
zacks.com
Wednesday, 23 October 2024
businesswire.com
Tuesday, 24 September 2024
businesswire.com
Friday, 30 August 2024
zacks.com
fxempire.com
Monday, 19 August 2024
seekingalpha.com
Wednesday, 7 August 2024
investors.com
Sunday, 4 August 2024
investorplace.com
Friday, 2 August 2024
zacks.com
zacks.com
zacks.com
Wednesday, 31 July 2024
zacks.com
seekingalpha.com
zacks.com
zacks.com
zacks.com
zacks.com
Tuesday, 30 July 2024
zacks.com
  • What's the price of United Therapeutics stock today?

    One share of United Therapeutics stock can currently be purchased for approximately $313.22.

  • When is United Therapeutics's next earnings date?

    Unfortunately, United Therapeutics's (UTHR) next earnings date is currently unknown.

  • Does United Therapeutics pay dividends?

    No, United Therapeutics does not pay dividends.

  • How much money does United Therapeutics make?

    United Therapeutics has a market capitalization of 16.07B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 20.2% to 2.33B US dollars.

  • What is United Therapeutics's stock symbol?

    United Therapeutics Corporation is traded on the NASDAQ under the ticker symbol "UTHR".

  • What is United Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of United Therapeutics?

    Shares of United Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are United Therapeutics's key executives?

    United Therapeutics's management team includes the following people:

    • Dr. Martine A. Rothblatt Founder, Chairman & Chief Executive Officer(age: 70, pay: $3,240,000)
    • Mr. Michael I. Benkowitz Pres & Chief Operating Officer(age: 53, pay: $1,960,000)
    • Mr. Paul A. Mahon Executive Vice President, Gen. Counsel & Corporation Sec.(age: 61, pay: $1,670,000)
    • Mr. James C. Edgemond Chief Financial Officer & Treasurer(age: 57, pay: $1,420,000)
  • Is United Therapeutics founder-led company?

    Yes, United Therapeutics is a company led by its founder Dr. Martine A. Rothblatt.

  • How many employees does United Therapeutics have?

    As Jul 2024, United Therapeutics employs 1,168 workers.

  • When United Therapeutics went public?

    United Therapeutics Corporation is publicly traded company for more then 26 years since IPO on 17 Jun 1999.

  • What is United Therapeutics's official website?

    The official website for United Therapeutics is unither.com.

  • Where are United Therapeutics's headquarters?

    United Therapeutics is headquartered at 1040 Spring Street, Silver Spring, MD.

  • How can i contact United Therapeutics?

    United Therapeutics's mailing address is 1040 Spring Street, Silver Spring, MD and company can be reached via phone at +30 16089292.

  • What is United Therapeutics stock forecast & price target?

    Based on 4 Wall Street analysts` predicted price targets for United Therapeutics in the last 12 months, the avarage price target is $458. The average price target represents a 46.22% change from the last price of $313.22.

United Therapeutics company profile:

United Therapeutics Corporation

unither.com
Exchange:

NASDAQ

Full time employees:

1,168

Industry:

Biotechnology

Sector:

Healthcare

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

1040 Spring Street
Silver Spring, MD 20910

CIK: 0001082554
ISIN: US91307C1027
CUSIP: 91307C102